TB-500 benefits plateau at standard loading doses
Recommended investigations include: Full blood count with blood film examination Serum vitamin B12 level Serum folate (to exclude combined deficiency) Intrinsic factor antibodies Thyroid function tests (autoimmune association) Consider MMA and homocysteine if diagnosis uncertain and available Neurological examination should be performed in all patients, assessing for peripheral neuropathy, proprioception loss, and signs of subacute combined degeneration of the spinal cord
The reality is stark: these medications can cost upwards of $1,000 per month without insurance coverage
Users often report increased energy, enhanced focus, and noticeable reduction in stubborn fat
Promising new candidates include: Amycretin (Novo Nordisk) Orforglipron (Eli Lilly) Survodutide (Boehringer Ingelheim) VK2735 (Viking Therapeutics) MariTide (Amgen) Retatrutide (Eli Lilly) Among the most closely watched candidates is retatrutide, a triple-agonist developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors